Eton Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Eton Pharmaceuticals, Inc. on April 16, 2026. The filing discloses a significant change in executive leadership regarding the Chief Financial Officer (CFO) position.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Appointment of New CFO: Judith Matthews was appointed Executive Vice President, Accounting and Finance, effective April 16, 2026. She will assume the role of Chief Financial Officer, Corporate Secretary, and Treasurer effective June 1, 2026.
- Departure of Current CFO: James Gruber will step down as CFO on May 31, 2026. He will remain with the company through that date and subsequently enter a six-month consulting agreement.
- Compensation Package: Ms. Matthews' package includes a $440,000 annual base salary, a discretionary incentive bonus with a target of 45% of base salary, and a one-time stock option grant for 37,000 shares vesting over four years.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of material risks and contingencies. It notes that the selection of Ms. Matthews was not pursuant to any arrangement with other persons and that no reportable family relationships or transactions exist under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the effective date of the CFO transition (June 1, 2026) and the interim period coverage.
- Review the terms of the six-month consulting agreement for the outgoing CFO, James Gruber.
- Confirm the vesting schedule and exercise price of the 37,000 stock options granted to Ms. Matthews.
- Check for any subsequent filings regarding the performance targets for the discretionary bonus.